Atrium Therapeutics Insider Trades
NASDAQ: RNAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Last 12 months
- Purchases
- 0 · $0
- Sales
- 0 · $0
- Shares bought / sold
- 0 / 0
- Net activity
- Net buying $0
Atrium Therapeutics insider activity
Over the last 12 months, Atrium Therapeutics insiders reported 14 transactions on SEC Form 4: 0 open-market purchases and 0 sales. The most recent filing shows Flanagan W. Michael (Director) reporting a transaction in 22,812 shares at $8.95 on Sep 18, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put RNA's ownership changes in context.
Summary generated from market data by MetaCap's automated system. Methodology
RNA insider transactions
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Sep 18, 2026 | Hoyos Rocio MartinChief Strategy Officer | Tax withholding | 8,320 | $74.46K | Form 4 |
| Sep 18, 2026 | Winslow Brendan R.Chief Financial Officer | Tax withholding | 6,742 | $60.34K | Form 4 |
| Sep 18, 2026 | Gallagher Kathleen P.See Remarks | Tax withholding | 11,632 | $104.11K | Form 4 |
| Sep 18, 2026 | Kenney StephanieSee Remarks | Tax withholding | 2,375 | $21.26K | Form 4 |
| Sep 18, 2026 | Hughes Steven GeorgeChief Medical Officer | Tax withholding | 21,459 | $192.06K | Form 4 |
| Sep 18, 2026 | Younis HusamChief Scientific Officer | Tax withholding | 11,216 | $100.38K | Form 4 |
| Sep 18, 2026 | Boyce SarahDirector | Tax withholding | 126,418 | $1.13M | Form 4 |
| Sep 18, 2026 | Flanagan W. MichaelDirector | Tax withholding | 22,812 | $204.17K | Form 4 |
| Apr 20, 2026 | Hoyos Rocio MartinChief Strategy Officer | Award | 30,000 | — | Form 4 |
| Apr 20, 2026 | Hughes Steven GeorgeChief Medical Officer | Award | 30,000 | — | Form 4 |
| Apr 20, 2026 | Younis HusamChief Scientific Officer | Award | 30,000 | — | Form 4 |
| Apr 20, 2026 | Gallagher Kathleen P.See Remarks | Award | 102,500 | — | Form 4 |
| Apr 20, 2026 | Winslow Brendan R.Chief Financial Officer | Award | 30,000 | — | Form 4 |
| Apr 20, 2026 | Kenney StephanieSee Remarks | Award | 30,000 | — | Form 4 |
Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4